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http://www.biomedcentral.com/1471-2407/13/220RESEARCH ARTICLE Open AccessHuman Papillomavirus-associated oropharyngeal
cancer: an observational study of diagnosis,
prevalence and prognosis in a UK population
Mererid Evans1, Robert Newcombe2, Alison Fiander3, James Powell1, Martin Rolles4, Selvam Thavaraj5,
Max Robinson6 and Ned Powell7*Abstract
Background: The incidence of Human Papillomavirus (HPV) associated oropharyngeal cancer (OPC) is increasing.
HPV-associated OPC appear to have better prognosis than HPV-negative OPC. The aim of this study was to robustly
determine the prevalence of HPV-positive OPC in an unselected UK population and correlate HPV positivity with
clinical outcome.
Methods: HPV testing by GP5+/6+ PCR, In Situ Hybridisation (ISH) and p16 immunohistochemistry (IHC) was
performed on 138 OPCs diagnosed in South Wales (UK) between 2001–06. Kaplan-Meier analysis was used to
correlate HPV status with clinical outcome.
Results: Using a composite definition of HPV positivity (HPV DNA and p16 overexpression), HPV was detected in
46/83 (55%) samples where DNA quality was assured. Five year overall survival was 75.4% (95% CI: 65.2 to 85.5) in
HPV-positives vs 25.3% (95% CI: 14.2 to 36.4) in HPV negatives, corresponding to a 78% reduction in death rate
(HR 0.22, p < 0.001). HPV-positives had less locoregional recurrence but second HPV-positive Head and Neck
primaries occurred. Poor quality DNA in fixed pathological specimens reduced both HPV prevalence estimates and the
prognostic utility of DNA-based HPV testing methods. As a single marker, p16 was least affected by sample quality and
correlated well with prognosis, although was not sufficient on its own for accurate HPV prevalence reporting.
Conclusions: This study highlights the significant burden of OPC associated with HPV infection. HPV positive cases are
clinically distinct from other OPC, and are associated with significantly better clinical outcomes. A composite definition
of HPV positivity should be used for accurate prevalence reporting and up-front DNA quality assessment is
recommended for any DNA-based HPV detection strategy.
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Squamous cell carcinoma of the oropharynx, affecting
the tonsils, base of tongue, pharyngeal wall and soft
palate, has increased in incidence in developed countries
over the last 20 years [1,2]. This increase has been attri-
buted to Human Papillomavirus (HPV). In Sweden, a
doubling in tonsil cancer incidence prompted reports of
an ‘epidemic of a virus-induced carcinoma’ [1]. HPV
prevalence rates in oropharyngeal cancer (OPC) range* Correspondence: powellng@cf.ac.uk
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reproduction in any medium, provided the orfrom 36% to >80%, varying with geographical location
and anatomical subsite [3-5]. It is likely that population-
specific incidence rates of HPV-induced OPC are
influenced by oral HPV infection rates, sexual behaviour,
and rates of smoking and drinking. Among HPV positive
OPC, HPV16 is the predominant genotype, accounting
for approximately 95% of cases [6].
Whereas virtually all cervical cancers are HPV-
induced, OPC has two distinct aetiologies: consumption
of tobacco and alcohol, or HPV infection, which may
co-exist [5]. Until recently, the relevant aetiological
agent in an individual patient was unknown but making
this distinction is clinically important because HPV-td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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therapy, chemoradiotherapy (CRT) and radiotherapy (RT)
and has a better prognosis compared to HPV-negative
OPC [6-10]. Better outcomes have also been reported
after surgery, suggesting that improved outcomes in HPV-
positive patients are independent of treatment received
[3,11]. Other factors, particularly tobacco smoking, may
adversely affect prognosis in HPV-positive OPC [5,7].
A variety of HPV detection methods are available and
differences in test characteristics may partly explain the
variation in HPV prevalence rates reported in different
studies [12]. Because the presence of HPV DNA in a
tumour per se is not evidence of a causal relationship, a
marker of HPV activity is needed to diagnose HPV-
induced OPC. A widely used ‘surrogate’ biomarker of
HPV activity, is p16 immunohistochemistry (IHC). p16 is
a cyclin-dependent-kinase inhibitor and is induced as a
consequence of inhibition of Rb activity by the HPV E7
oncoprotein (in most other Head and Neck (H&N)
cancers, p16 is down regulated). Two main diagnostic
algorithms have emerged for use in the clinical setting:
both advocate screening by p16 IHC followed by detection
of HPV DNA, either by consensus PCR or In Situ Hybri-
dization (ISH) [13,14].
This study aimed to determine the prevalence of HPV-
associated OPC in South Wales (UK) and investigate the
diagnostic and prognostic utility of GP5+/6+ PCR en-
zyme immunoassay, ISH and p16 IHC. Most published
data relating HPV status with clinical outcome is based
on clinical trial cohorts and, while this enables collection
of high quality clinical data, it results in exclusion of
some patient groups, including palliative patients. This
study did not systematically exclude any patients and
demonstrates the impact of HPV status on outcome in a
‘real-world’ population of patients with OPC. This pro-
vides insight into the behaviour and late outcomes of
HPV-positive OPC.
Methods
Study population
Patients diagnosed with OPC (ICD-10 codes C01, C05.1,
C05.2, C09, C10) in South Wales (UK) 1/9/2001-31/8/
2006 were identified from pathology databases. Data on
clinicopathological characteristics and outcome were
obtained from an electronic health record used at the
regional Cancer Centre. Deaths in peripheral hospitals
were automatically fed into the electronic record. Where
cause of death was not documented on the electronic
record, it was elucidated by review of patient notes,
review of clinic letters and/or discussion with General
Practitioners. For every patient who was alive at the
point of analysis but had not been seen in hospital for
the preceding 12 months (eg had been discharged from
follow-up), the study team contacted the GeneralPractitioner to ensure that the patient was indeed still
alive with no evidence of disease recurrence. Where
smoking history was available, patients were classified as
current, never or previous smokers (stopped smoking
>3 months before diagnosis). Locoregional recurrence
was defined as recurrence at the primary site and/or
cervical lymph nodes after a complete response to
treatment.
One representative formalin fixed paraffin embedded
(FFPE) block was retrieved for each case. Histological
diagnosis of squamous carcinoma of the oropharynx was
confirmed by two pathologists with special interest in
OPC (MR and ST).
Approval for the study was obtained from South East
Wales Research Ethics Committee (ref: 09/WSE03/44).
HPV detection
DNA extraction and assessment of sample adequacy
Sectioning was performed with appropriate precautions
to prevent inter-block DNA contamination (eg thorough
cleaning of microtome, use of fresh blades). DNA was
extracted from 2 × 10 μm sections of FFPE biopsies
using the Qiagen FFPE Kit (Qiagen, Hilden, Germany).
DNA quality was assessed by PCR for a 119 bp fragment
of the human HMBS gene. To control for contamination
during sectioning, regular sections were cut from a
blank paraffin block and processed in parallel with the
tumour sections. Positive (HPV16 positive Caski cell line
DNA) and negative (water) controls were included for
each PCR run. All blanks and negative controls tested
negative for HMBS and HPV DNA.
GP5+/6+ PCR enzyme immune assay (EIA)
Samples were genotyped for HPV DNA by GP5+/6+
PCR EIA. HPV typing was performed in 2 stages the
first stage used cocktails of probes for 14 high risk and 6
low risk HPV types; PCR was then repeated on positive
samples, which were then typed with individual probes
[15]. This assay detects DNA from high risk HPV types:
16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68;
and low risk types: 6, 11, 40, 42, 43 and 44. Full details
of the HMBS PCR and GP5+/6+ PCR EIA are provided
in Additional file 1.
High-risk HPV in situ hybridisation
High-risk HPV ISH was performed using the Inform HPV
III Family 16 Probe, (Ventana Medical Systems Inc, USA)
on a Benchmark Autostainer (Ventana Medical Systems)
for HPV types 16, 18, 31, 33, 35, 39, 51, 52, 56, 58 and 66.
CaSki cells (HPV16 positive; 200–400 copies/cell), HeLa
cells (HPV18 positive; 10–50 copies/cell) and C-33A
(HPV negative) were used as controls. The HR-HPV ISH
test was scored as positive if blue reaction product
colocalised with the nuclei of malignant cells. Diffuse
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staining were scored as positive. Focal specific staining of
only part of the tumour section was regarded as positive.
Diffuse staining of tumour and stromal tissues, considered
to represent non-specific chromogen precipitate, was
scored as negative.
p16 immunohistochemistry
p16 IHC was carried out using the CINtec Histology
kit (mtm Laboratories, AG, Germany) on a Ventana
Benchmark Autostainer. A tonsil SCC with high p16
expression was used as a positive control. The primary
antibody was omitted from negative controls. p16 IHC
was scored as positive if there was strong and diffuse
nuclear and cytoplasmic staining present in greater than
70% of the malignant cells. All other staining patterns
were scored as negative. All samples were scored inde-
pendently by two expert H&N pathologists and discord-
ant cases were reviewed to come to a consensus score.
Both ISH and p16 IHC were carried out at the Depart-
ment of Cellular Pathology, Newcastle, UK as previously
described [14].
Interpretation of HPV test results
A binary classification (positive vs negative) was used to
score the p16 IHC and HPV ISH. Stained sections were
assessed independently by two pathologists, who met to
resolve discordant interpretations and establish a consen-
sus categorization. For PCR-EIA, positivity was defined as
giving an absorbance at 405 nm of greater than three
times background.
Statistical methods
Overall Survival (OS) analyses were based on time from
diagnosis to death; survivors were censored at their last
follow-up. Progression Free Survival (PFS) analyses were
based on time from diagnosis to first event (locoregional
recurrence, distant metastasis or death from any cause);
patients without an event were censored at their last
follow-up. Analyses of OS and PFS included all patients,
irrespective of treatment intent and response to treat-
ment. Kaplan-Meier analysis was used to obtain survival
plots and 3- and 5-year survival. The Cox proportional
hazards model was used to estimate Hazard Ratios (HR)
characterising the independent prognostic significance of
single and multiple variables, namely HPV and smoking
status/treatment method. Further analyses for variables
including age and stage were not performed as sub-
groups were insufficient to be statistically robust.
Results
Histology blocks were obtained for 147 cases, representing
83% of patients diagnosed with OPC in South Wales
during the period. Nine blocks did not contain sufficienttumour for analysis. Analyses are presented for 138 pa-
tients with histologically confirmed squamous OPC.
HPV prevalence
Tumours were classified as HPV-positive if they contained
HPV DNA (by GP5+/6+ PCR and/or ISH) and over-
expressed p16 [13,14]. Four groups were defined: ‘true’
HPV positives, ‘true’ HPV negatives and two ‘equivocal’
groups (Table 1) as described by Weinberger et al. [16].
The overall HPV prevalence rate was 55% (46/83)
(95% CI: 45–66) when DNA quality was assured. HPV
prevalence fell to 50% (69/138) (95% CI: 42–58) if HMBS
negative cases were included, consistent with the occur-
rence of some HPV DNA false negative results in samples
containing poor quality DNA (see below).
Among cases that tested positive for HPV by GP5+/6+
PCR, 97% (67/69) were positive for HPV16. One case
contained HPV33 and one case showed co-infection
with HPV18 and HPV56. No low-risk HPV infections
were detected.
Influence of DNA quality on HPV detection rate
DNA quality was assessed by PCR for the human HMBS
gene which was amplifiable in 83/138 cases (60%),
suggesting high levels of DNA degradation in the other
samples. DNA adequacy ranged from 30% in hospitals
using unbuffered formalin as a fixative to 96% in those
using neutral buffered formalin.
HPV testing was carried out on all samples regardless of
DNA quality. This revealed a high false negative rate when
DNA-based HPV detection methods (PCR and ISH) were
used on samples containing poor quality DNA (HMBS
negative) e.g. HPV DNA positivity by GP5+/6+ PCR was
23% lower in HMBS negative than HMBS positive cases.
DNA degradation did not have a significant effect on p16
IHC testing results. Estimated false negative rates are
shown in Table 2.
Agreement between HPV testing methods
In samples with good quality DNA (HMBS positive), the
proportion of positive samples was similar when
analysed by p16 (47/83 cases, 57%) and GP5+/6+ PCR
(49/83, 59%) and slightly lower using ISH (42/83, 51%).
When samples containing poor quality DNA were
included, prevalence rates by GP5+/6+ PCR and ISH
were lower (50% and 43% respectively), consistent with
the presence of false negatives in this group. Concordance
between tests was highest for p16 and GP5+/6+ PCR
(5% of cases discordant) than for either test with ISH (11%
discordant for each). The number of discordant cases
increased for each comparison if HMBS negatives were
included showing that poor DNA quality reduced
consistency between HPV testing results, as well as overall
Table 1 Baseline characteristics of patients and tumours grouped by HPV results
All 138
patients
Group 1 (n = 59)
‘True’ negatives
p16 negative PCR &
ISH negative
Group 2 (n = 6)
'Equivocal'
p16 negative PCR &/or
ISH positive
Group 3 (n = 69)
‘True’ positives
p16 positive PCR &/or
ISH positive
Group 4 (n = 4)
'Equivocal'
p16 positive PCR &
ISH negative
Test
comparing
groups 1 & 3
Male 104 (75%) 44 (75%) 5 51 (74%) 4 X21: p = 0.93
Female 34 (25%) 15 (25%) 1 18 (26%) 0
Age in years
Mean (SD)
58.1 (10.7) 61.6 (10.1) 57 (7.9) 55.7 (10.9) 48.8 (0.5) t: p = 0.002
Smoking*
Current 63 (55%) 41 (80%) 4 18 (32%) 0 X22: p < 0.001
Previous 32 (28%) 9 (18%) 0 23 (41%) 0
Never 20 (17%) 1 (2%) 2 15 (27%) 2
Performance status
0 68 (49%) 15 (25%) 4 46 (67%) 3 MW: p < 0.001
1 42 (30%) 21 (36%) 1 19 (28%) 1
2 21 (15%) 17 (29%) 0 4 (6%) 0
3 7 (5%) 6 (10%) 1 0 (0%) 0
Primary tumour site
Tonsil 93 (67%) 33 (56%) 4 54 (78%) 2 X22: p < 0.001
Tongue base
or vallecula
35 (25%) 16 (27%) 2 15 (22%) 2
Other1 10 (7%) 10 (17%) 0 0 (0%) 0
AJCC stage
I 5 (4%) 5 (8%) 0 0 (0%) 0 MW: p = 0.53
II 5 (4%) 3 (5%) 0 2 (3%) 0
III 28 (20%) 8 (14%) 0 20 (29%) 0
IVA 87 (63%) 35 (59%) 5 43 (62%) 4
IVB 8 (6%) 3 (5%) 1 4 (6%) 0
IVC 5 (4%) 5 (8%) 0 0 (0%) 0
Primary treatment
Surgery 71(51%) 21 (36%) 4 42 (61%) 4 X21: p = 0.07
Radiotherapy 55 (40%) 27 (46%) 1 27 (39%) 0
Radical 126 (91%) 48 (81%) 5 69 (100%) 4 X21: p = 0.001
Palliative 12 (9%) 11 (19%) 1 0 (0%) 0
DNA Adequacy
HMBS
positive
83 32 (39%) 4 (5%) 46 (55.4%) 1 (1%)
HMBS
negative
55 27 (49%) 2 (4%) 23 (42%) 3 (5%)
All cases 138 59 (43%) 6 (4%) 69 (50%) 4 (3%)
Tests used: X21 - chi-square on 1 degree of freedom (df); X
2
2 - chi-square on 2 df; t- independent samples t-test; MW Mann–Whitney test.
AJCC - American Joint Committee on Cancer, SD - Standard deviation.
* Analyses for smoking exclude 23 cases with smoking history unknown.
1Other: includes soft palate, uvula and posterior pharyngeal wall.
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shown in Table 3.
Prognostic value of HPV testing methods
Individually, each HPV testing method was highly prog-
nostic for Overall Survival (OS) and Progression FreeSurvival (PFS). When all cases were included, p16
correlated well with prognosis (point estimate of HR for
death 0.24, 95% CI 0.15-0.39), as did ISH (0.27, 95% CI
0.16-0.46) and GP5+/6+ PCR (0.29, 95% CI 0.18-0.47),
although all were slightly inferior to the composite defin-
ition of HPV-positivity (0.22, 95% CI 0.13-0.37), and no
Table 2 Estimation of false negatives among 55 HMBS negative cases
HPV marker Observed HPV positives among Chi-square test
for association between
observed HPV
status and HMBS
Estimated false negatives for HPV
among 55 HMBS negative cases
HMBS
positive n = 83
HMBS
negative n = 55
Number As proportion of 55
HMBS negative cases
95% confidence
interval
GP5+/6+ PCR 49 (59%) 20 (36%) p = 0.009 12.5 23% 6% to 38%
ISH 42 (51%) 18 (33%) p = 0.04 9.8 18% 1% to 33%
p16 47 (57%) 26 (47%) p = 0.28 5.1 9% 0%* to 26%
For GP5+/6+ PCR, number of false negatives estimated as 49 × 55/83 – 20 = 12.5, representing 23% of HMBS negative cases. The same method was used to
calculate false negative rates for ISH and p16.
*95% confidence interval extends below 0 for p16 – shown truncated here.
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negative cases were excluded, the prognostic value of
GP5+/6+ PCR improved to equal that of the composite
marker and p16 (HR 0.20), suggesting that GP5+/6+ PCR
and p16 are equally prognostic when DNA quality is
assured. Hazard Ratios are shown in Table 4.
Patient characteristics
Baseline patient and tumour characteristics are shown in
Table 1. The proportion of HPV-positive cases was
similar in men and women, although men were more
frequently affected overall (75% cases). HPV-positive
patients were 6 years younger (p = 0.002), had better
performance status (p < 0.001) and were less likely to be
current smokers (p < 0.001) than HPV-negative patients.
HPV-positive cancers occurred exclusively in the tonsil
(78%) and tongue base (22%), whereas 17% of HPV-
negative cancers arose elsewhere in the oropharynx (soft
palate, uvula, posterior pharyngeal wall). Overall disease
stage was similar, although HPV-positive patients were
less likely to present with distant metastases (0% vs 8%,
p = 0.04). HPV-positive patients were treated radically
(curatively) more often than HPV-negative patients
(p < 0.001), 19% of whom were treated palliatively. Of
radically treated patients, 54% underwent primary surgery
(+/− post-operative RT) and 46% underwent primary RT
(+/− chemotherapy, CRT), reflecting local practice at the
time. There was a trend for more HPV-positive cases to
have primary surgery (42/69 cases, 61%) and more
HPV-negative cases to have primary RT/CRT (27/48,
56%) (p = 0.068). Patients treated with RT/CRT were olderTable 3 Concordance between HPV test results
P16 GP5+/6+ All cases
(n = 138)
HMBS positive cases
only (n = 83)
ISH - ISH + ISH - ISH +
- - 59 1 32 1
- + 3 2 2 1
+ - 4 5 1 0
+ + 12 52 6 40
The table shows results of the three tests for all cases and for HMBS positive
cases only. (−) indicates a negative test result; (+) indicates a positive
test result.(mean age 61 years) and had poorer performance status
than those treated surgically (mean age 52 years), in
keeping with different HPV prevalence in both groups.
Effect of HPV on survival and recurrence
After median follow-up from diagnosis of 4.9 years
(range 0.1 to 10.1 years), 77 deaths occurred in 138
patients. Overall Survival (OS) by Kaplan-Meier survival
analysis was 59.4% at 3 years (95% CI: 51.2 to 67.6) and
52.2% at 5 years (95% CI: 43.8 to 60.5). No significant
difference in survival was seen when HMBS negative
cases were excluded from the analysis and, as a result,
HMBS positive and negative cases were combined for
subsequent analyses, although every analysis was re-
peated in HMBS positive cases only to ensure that the
results were consistent (data not shown). For 126 radi-
cally treated patients, OS was 65.1% at 3 years and
57.1% at 5 years. For the 12 palliative patients, median
survival was 186 days (6 months), range 28–802 days.
A clear association between HPV-positivity and favou-
rable prognosis was demonstrated in Kaplan-Meier
analysis (Figure 1A). 3 and 5-year OS rates were 82.6%
(95% CI: 73.7 to 91.5) and 75.4% (95% CI: 65.2 to 85.5)
respectively in HPV-positive patients, compared to
32.2% (95% CI: 20.3 to 44.1) and 25.3% (95% CI: 14.2 to
36.4) in HPV-negative patients, corresponding to a 78%
reduction in death rate associated with HPV-positivity
(HR 0.220, 95% CI; 0.132-0.366, p < 0.001). Survival in
patients with equivocal HPV status (n = 10) was
intermediate between that of ‘true’ HPV-positives and
negatives (Figure 1B). The effect of HPV status remained
highly significant when palliative patients were excluded;
OS at 3 and 5-years in radically treated HPV-positive
patients was 82.6% and 75.4%, compared to 39.6% (95%
CI: 32.5-46.7) and 31.1% (95% CI: 24.4-37.6) in HPV-
negative patients, corresponding to a 74% reduction in
the death rate (HR 0.259, 95% CI 0.152-0.440, p < 0.001).
At last follow-up, 87 patients (63%) had suffered an
event (progression, recurrence or death). For HPV-
positive patients, 3 and 5-year Progression Free Survival
(PFS) rates were 72.5% (95% CI: 61.9 to 83.0) and 68.1%
(95% CI: 57.1 to 69.1), compared to 25.4% (95% CI: 14.3
to 36.5) and 17% (95% CI 7.4 to 26.5) in HPV negatives,
Table 4 Prognostic ability of individual HPV detection methods
Group p16 ISH GP5+/6+ PCR
All cases (n = 138) 0.24 (0.15-0.39) 0.27 (0.16-0.46) 0.29 (0.18-0.47)
All cases excluding equivocals (n = 128) 0.22* (0.13-0.37) 0.25 (0.14-0.43) 0.26 (0.16-0.44)
HMBS positive cases (n = 83) 0.20 (0.10-0.37) 0.33 (0.18-0.62) 0.22 (0.12-0.41)
HMBS positive cases excluding equivocals (n = 78) 0.20* (0.10-0.38) 0.27 (0.14-0.53) 0.20 (0.10-0.38)
Hazard ratios (HR) for overall survival, with 95% confidence intervals, are shown for each HPV testing method.
* When ‘equivocal’ cases (with discrepant p16 and HPV DNA testing results) are excluded, analyses for p16 and the composite criterion for HPV positivity based on
3 markers are equivalent and represent the ‘gold standard’.
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Figure 1 Kaplan-Meier plots. A. Overall survival by HPV status. Blue solid line: HPV-positive patients (n = 69), red dotted line: HPV-negative
patients (n = 59). 10 patients with equivocal HPV status are excluded. B. Overall survival in 4 groups classified by p16 expression and presence of
HPV DNA. Blue solid line: HPV-positive (Group 3, n = 69), brown dashed/dotted line: p16 negative and ISH/PCR positive (Group 2, n = 6), green
dashed line: p16 positive and ISH/PCR negative (Group 4, n = 4), red dotted line: HPV negative (Group 1, n = 59). C. Progression free survival by
HPV status. Blue solid line: HPV-positive patients (n = 69), red dotted line: HPV-negative patients (n = 59). 10 patients with equivocal HPV status are
excluded. D. Progression free survival in radically treated patients by HPV status. Blue solid line: HPV-positive patients (n = 69), red dotted line:
HPV-negative patients (n = 48). 21 patients with equivocal HPV status or palliative intent are excluded. E. Overall survival by HPV and smoking
status. Blue solid line: HPV-positive not current smokers (n = 38), green dashed line: HPV-positive current smokers (n = 18), red dotted line: HPV-
negative current smokers (n = 41), brown dotted/dashed line: HPV-negative not current smokers (n = 10). Cases with equivocal HPV status or
unknown smoking status are excluded. F. Overall survival by smoking status. Blue solid line: non-smokers (n = 20), green dashed line: previous
smokers (n = 32), red dotted line: current smokers (n = 63). Cases with unknown smoking status are excluded.
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sion, relapse or death associated with HPV-positivity
(HR 0.25, 95% CI 0.15 to 0.39, p < 0.001) (Figure 1C). As
with OS, PFS in patients with equivocal HPV status was
intermediate between that of ‘true’ HPV-positives and
negatives. PFS at 3 and 5-years in radically treated HPV-
positive patients was 72.5% and 68.1%, compared to
31.2% and 20.8% in HPV-negative patients, correspon-
ding to a 72% reduction in the rate of relapse or death
(HR 0.28, 95% CI 0.17-0.46, p < 0.001) (Figure 1D).
Kaplan-Meier analysis of survival by HPV and smoking
status simultaneously demonstrated a significant survival
advantage associated with HPV-positivity, regardless of
smoking status (Figure 1E). Survival was significantly
better in previous and never smokers than in current
smokers (HR for death by not current smoking 0.48,
95% CI 0.28-0.81, p = 0.006) (Figure 1F); Cox regression
analysis showed that this was due entirely to their ten-
dency to be HPV-positive. HPV-positivity was also asso-
ciated with better survival regardless of primary
treatment modality (surgery or RT/CRT). Although OS
and PFS were better in surgically treated patients overall
than those treated with primary RT/CRT (HR 0.5 for
surgery; 95% CI: 0.3-0.83, p = 0.007), a higher proportion
of the surgical group were HPV-positive (66.7% vs 50%,
p = 0.068); using Cox regression analysis to adjust for HPV
status, the survival difference between the two groups was
no longer statistically significant (HR 0.74, p = 0.36).
Locoregional recurrence rates were lower in HPV-
positive than HPV-negative patients (8/69, 12% vs 16/59,
27%) whereas distant metastases occurred at similar
rates (4/69, 8% vs 5/59, 6%), mostly in lungs/bones
(Table 5). Second primary cancers occurred in 12% of
patients overall, only slightly more frequently in HPV-
negative (8/59, 13.6%) than HPV-positive (8/69, 11.6%)
patients. Almost all second primaries in HPV-negative
patients (7/8) occurred outside the H&N (mostly in the
lung); the single case arising in the H&N (oropharynx)
was HPV-negative. In contrast, three (3/8) second
primaries occurred in the H&N in HPV-positive patients
(1 sarcoma in a previous RT field was not analysed
further): 1 patient developed a HPV16-positive poorly
differentiated squamous carcinoma of the nasopharynxTable 5 Second primary malignancy and recurrence (local/dis
HPV status All cases
‘True’ negatives (Group 1) p16 negative, PCR & ISH negative 59
‘Equivocal' (Group 2) p16 negative, PCR &/or ISH positive 6
‘True’ positives (Group 3) p16 positive, PCR &/or ISH positive 69
‘Equivocal' (Group 4) p16 positive, PCR & ISH negative 4
Total 138
Head and Neck (H&N), Distant Metastases (DM), Second Primary Malignancy (SPM).(negative for EBV on EBER ISH) 7 months after a
HPV16-positive tonsillar cancer and 1 patient developed
a HPV16-positive squamous carcinoma of the tongue
base 7 years after a HPV16-positive tonsillar cancer.
Discussion
Biologically relevant HPV infection, defined as presence of
HPV DNA by ISH and/or PCR and p16 over-expression,
was identified in 55% of patients diagnosed with OPC in
South Wales (UK), 2001–2006. The survival advantage
afforded by HPV in a ‘real world’ population of patients
with OPC, including those managed palliatively, is clearly
demonstrated as is the effect of HPV on the long-term
clinical behaviour of the disease. The effect of poor quality
DNA in fixed pathological specimens on the diagnostic
and prognostic utility of DNA-based HPV testing
methods, including ISH, is shown for the first time. P16
expression is not affected by DNA quality and may be
utilized as a single marker of HPV infection in clinical
practice, although a composite definition of HPV posi-
tivity is recommended for accurate HPV prevalence
reporting.
HPV prevalence rates differ between different geograph-
ical regions and time periods. The rate in this study (55%)
is consistent with international (51.2% (88/172)) and US
series (59.4% (192/323)) collected between 2002–2005
[7,17]. It also adds to a picture of regional and temporal
variation in HPV prevalence across the UK where rates of
37.5% (33/88) and 42.7% (77/180) have been reported
[12,18]. The number of ‘equivocal’ cases with discrepant
HPV DNA and p16 testing results was significantly lower
than in some other studies [7,18], suggesting that a testing
algorithm combining PCR and ISH increases sensitivity
for HPV DNA detection [14]. Discordant HPV DNA and
p16 testing results occurred in 6-7% of cases showing that
p16 alone is not sufficient for studies that aim to accu-
rately report HPV prevalence.
Poor quality DNA significantly reduced HPV prevalence
estimates using PCR and ISH-based techniques, because
of the occurrence of false negative results in samples
containing degraded DNA. Although PCR-based testing
protocols routinely incorporate assessment of DNA qua-
lity, DNA-based ISH techniques do not, and therefore risktant) by HPV status
Site of recurrence Second Primary Malignancy (SPM)
None H&N DM HN+ DM No SPM SPM H&N Other SPM
39 15 4 1 51 1 7
4 1 1 0 5 0 1
57 8 4 0 61 3 5
2 1 1 0 4 0 0
102 25 10 1 121 4 13
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the lower sensitivity reported for ISH compared to other
HPV detection methods in previous studies [17]. However
a recently developed RNA-based ISH test for HPV does
include a control for sample quality and shows conside-
rable promise as a diagnostic marker for OPC [19]. The
three HPV testing methods evaluated in this study were
all good markers of survival, with no test performing
significantly better than another. Hazard ratios (HR) for
death were: 0.24 for p16, 0.27 for ISH, 0.29 for GP5+/6+
PCR and 0.22 for the composite definition of HPV positi-
vity. Poor quality DNA reduced the prognostic value of
DNA-based HPV testing methods and when poor quality
samples were excluded, the prognostic value of GP5+/6+
PCR was similar to that of p16 and the composite marker
(0.22). The effect of poor quality DNA on prevalence and
prognostication is reduced by using the composite defi-
nition of HPV-positivity.
The clinical implications of HPV positivity in this
unselected population of patients are clear. HPV positivity
was associated with a 78% reduction in death rate (HR
0.22) and a 75% reduction in rate of progression, relapse
or death (HR 0.25). This effect is greater than in many
clinical trial cohorts, due in part (but not entirely) to the
inclusion of palliative patients. Survival of radically treated
HPV-positive patients was comparable to that reported in
a large US study; 3y OS was 82.6% (95% CI: 73.7 to 91.5)
compared to 82.4% (95% CI: 77.2-87.6) and 3y PFS was
72.5% (95% CI: 61.9 to 83.0) compared to 73.7% (95% CI:
67.7 to 79.8). Survival of radically treated HPV-negative
patients was however significantly worse; 3y OS was
39.6% (95% CI: 32.5 to 46.7) compared to 57.1% (95% CI:
48.1-66.1) and 3y PFS was 31.2% (95% CI: 18.3 to 44.1)
compared to 43.4% (95% CI: 34.4-52.4) [7]. Similarly low
survival figures for HPV-negative OPC have been reported
previously [20] and poor performance status (~30% would
have been excluded from the US study on this basis) and
infrequent use of concurrent chemotherapy (<30% vs
100% in the US study) may have affected outcome in this
study. Their prognosis was poor regardless of whether
they were treated with primary surgery or RT/CRT.
The excellent outcomes of HPV-positive patients were
independent of smoking status or treatment method.
Retrospective analyses have suggested that smoking can
negatively affect survival in some HPV-positive patients
[5,7,21], and this data has influenced the design of
several clinical trials. Although the relatively small cohort
(n = 117) with known smoking history, crude definition of
smoking and/or large effect of HPV status on outcome
may have masked the effect of smoking in this study, it is
possible that the effect of smoking, particularly past smo-
king, on outcome from HPV-positive OPC has previously
been over-estimated, and this issue must be addressed
prospectively in future studies. There was a trend for moreHPV-positive patients to undergo primary surgery in this
study (p = 0.07); although HPV status was unknown when
treatment decisions were made, it is likely that selection of
younger, fitter patients for surgery, resulted in preferential
selection of HPV-positive patients. This highlights the
dangers of comparing outcomes from non-randomized
studies of surgery and RT/CRT, without knowledge of
HPV status; randomized trials with mandatory HPV test-
ing are required to assess treatments for OPC in future.
Improved outcomes in HPV-positive patients reflected
better locoregional control rates. In contrast, rates of
distant metastases occurring on follow-up were similar
in both HPV-positive and negative patients. The occu-
rrence of second HPV16-positive primaries, both in the
tongue base and nasopharynx (EBV-negative) in this
study is intriguing. Second HPV-associated cancers in
the tonsils and nasopharynx and HPV-positive/EBV-
negative nasopharyngeal carcinomas have previously
been reported [22-24] and it is possible that the lym-
phoid tissue throughout Waldeyer’s ring is particularly
susceptible to HPV-induced transformation. Second
primaries occurring in patients with a history of HPV-
positive OPC should be tested for HPV and further studies
to investigate the frequency and timing of HPV-positive
second H&N primaries are required to inform future
follow-up protocols.
There are several potential limitations to the study.
Histology blocks for 83% of OPC patients presenting
across South Wales over the study period were included.
There were several reasons why other cases were not
included: blocks were not collected from a number of
smaller centres, there was limited collection from one
major centre due to logistical difficulty in identifying the
relevant cases, mismatches were observed in coding bet-
ween registry and pathology databases, and some blocks
were missing from pathology archives. There is no reason
to suspect systematic bias in the sample, especially given
the multi-factorial reasons for samples not being included,
but the potential for some bias cannot be completely
excluded. The proportion of HPV-positive OPC is likely
to have increased since 2006 and the sample has limited
geographical representation, thus whilst it adds to the
picture of HPV prevalence in the UK, caution should be
exercised in generalising the findings.
Conclusions
HPV was responsible for the development of 55% of OPCs
in this study. Significantly better locoregional control and
survival were seen in HPV-positive cases. Given the sub-
stantial difference in prognosis, routine assessment of
HPV status should be mandated in clinical practice.
Standardisation of tests is clearly a significant issue but, as
a single marker, p16 IHC appears prognostic and is
unaffected by sample DNA quality, making it a useful test
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http://www.biomedcentral.com/1471-2407/13/220in clinical practice. P16 as a single marker is not sufficient
however for studies which aim to accurately report HPV
prevalence, when p16 coupled to at least one test for HPV
DNA (PCR/ISH) is recommended. Based on the study
results, it is recommended that any DNA-based HPV
detection strategy should incorporate up-front DNA qua-
lity assessment to reduce the effect of poor DNA quality
on HPV prevalence estimates.
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